Metabolic HealthSemaglutide and Tirzepatide Linked to Fewer Alcohol-Related Emergency Visits
Two diabetes medications may have benefits beyond blood sugar and weight management. Researchers compared electronic health records of adults with type 2 diabetes starting semaglutide, tirzepatide, or SGLT2 inhibitors. Over approximately ten to twelve months, semaglutide and tirzepatide were associated with 46% and 39% lower hazards, respectively, of hospitalizations or emergency visits for alcohol use disorder compared with SGLT2 inhibitors. Absolute rates were low: roughly two to five events per 1,000 person-years. There was no statistically clear difference between semaglutide and tirzepatide. These findings support further trials, but do not prove that either medication reduces drinking or prevents alcohol use disorder. Treatment decisions should still prioritize established benefits and risks. This observational study could not eliminate unmeasured differences between patients, and this summary is based only on the abstract.
